Clincosm LogoSign in Get a demo

Lung Ultrasonography in COVID-19 Pneumonia

Sponsor
Bursa Yüksek İhtisas Education and Research Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT04719234
Collaborator
(none)
60
Enrollment
1
Location
1
Arm
5.6
Actual Duration (Months)
10.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Lung ultrasonography has been used for diagnosis and treatment in many departments including intensive care before the pandemic. The gold standard method for the diagnosis of pneumonia is still chest tomography. Ultrasonography, which has advantages over tomography, has also been tried to be used in covid 19 pneumonia.

Condition or Disease Intervention/Treatment Phase
  • Device: lung ultrasonography
 N/A

Detailed Description

In this study, it was aimed to investigate the efficiency of lung ultrasonography in diagnosis of covid 19 pneumonia.

Study Design

Study Type:
Interventional
Actual Enrollment :
60 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Comparison of Lung Ultrasonography Findings With Chest Computerized Tomography Results in Corona virüs (COVID-19) Pneumonia
Actual Study Start Date :
Jun 15, 2020
Actual Primary Completion Date :
Dec 1, 2020
Actual Study Completion Date :
Dec 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Other: lung ultrasound

lung ultrasonography protocol will be applied.

Device: lung ultrasonography
Application of 12 zone lung ultrasonography protocol using the konvex ultrasound probe (2-6 MHz)

Outcome Measures

Primary Outcome Measures

  1. Relationship between Thoracic CT imaging results and LUS results [6 hours]

    Lung ultrasonography will be performed within 6 hours of the Thoracic CT.

Secondary Outcome Measures

  1. Characteristics of lesions [6 hours]

    İdentifying the characteristics of the abnormal findings detected in Thoracic CT and LUS

Other Outcome Measures

  1. the relation of the lesions with the pleura [6 hours]

    the relation of the lesions with the pleura, and their distance to the pleura.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • 18 and 85 years old

  • Hospitalized in intensive care unit

  • PCR tested

  • Thoracic CT applied

Exclusion Criteria:

  • Previous lung and thoracic wall surgery

  • Anatomically with thoracic wall disorder

  • Patients who did not consent to participate in the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital Bursa Turkey

Sponsors and Collaborators

  • Bursa Yüksek İhtisas Education and Research Hospital

Investigators

  • Principal Investigator: Korgün Ökmen, Assoc. PhD., Sağlık Bilimleri Üniversitesi Bursa Yüksek İhtisas Eğitim Ve Araştırma Hastanesi
  • Study Chair: Durdu Kahraman Yıldız, M.D, Sağlık Bilimleri Üniversitesi Bursa Yüksek İhtisas Eğitim Ve Araştırma Hastanesi
  • Study Chair: Emel Tatar Soyaslan, M.D, Sağlık Bilimleri Üniversitesi Bursa Yüksek İhtisas Eğitim Ve Araştırma Hastanesi

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Korgün Ökmen, Principal Investigator ,Assoc. PhD. M.D., Bursa Yüksek İhtisas Education and Research Hospital
ClinicalTrials.gov Identifier:
NCT04719234
Other Study ID Numbers:
  • 2011-KAEK-25 2020/5-21
First Posted:
Jan 22, 2021
Last Update Posted:
Jan 22, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
COVID-19
Pneumonia

Study Results

No Results Posted as of Jan 22, 2021